Friedberg on Moderna’s $500,000 Cancer ‘Vaccine’: The Science Is 30 Years Old, the Price Is a Scandal — BigGo Finance

When Moderna’s stock tripled this year on news that its personalized cancer therapy had shown positive trial results, the market treated it as a breakthrough moment. David Friedberg sees something closer to a heist. The science behind neoantigen immunotherapy, he argues, has been built over three decades — largely with taxpayer money. Clinics in Montana are already doing a version of it for $50,000. Moderna intends to charge $500,000.

“I’m actually pretty sad and frustrated and disappointed by this,” Friedberg said on the All-In Podcast. “I don’t think that this technique, which has been largely developed through several decades of iteration, research and development, which was largely funded by NIH and other public funding dollars… should now be patented, FDA approved and charged half a million dollars for people to get treated.”

The critique lands at a moment when Moderna — whose market cap jumped from $20 billion to $60 billion in 2026 — is betting its post-COVID future on this oncology franchise. The company recently proposed a $2 billion convertible note offering, suggesting it needs capital to scale the therapy. But Friedberg’s argument cuts deeper than valuation: he’s questioning whether a publicly funded scientific process should be privately monopolized at all.

The Science Is Not New

The core of Friedberg’s frustration is straightforward. Neoantigen therapy works by identifying proteins unique to a patient’s specific cancer — melanoma is particularly well-suited because UV light creates distinctive, targetable mutations. Researchers sequence the tumor’s DNA, identify those unique proteins, then manufacture a treatment that teaches the immune system to attack the cancer.

Moderna’s twist is using mRNA — the same platform behind its COVID vaccine — to make the patient’s own cells produce the target protein in vivo, rather than injecting a pre-made protein. That’s a delivery innovation, not a scientific revolution.

“I think what frustrates me the most about all of this, and everyone’s kind of lauding this as some unique breakthrough and special and powerful and it’s not,” Friedberg said, “because a lot of people are going to places like Montana and they are getting peptides printed for their particular cancer sequence and they are making their own neoantigens putting into their body and getting cured of their cancer.”

That’s the uncomfortable reality he’s pointing at: the process is already available, outside the FDA system, at a fraction of Moderna’s proposed price. Right-to-try laws and compounding pharmacies have created a gray market where cancer patients with means can access personalized neoantigen therapy for roughly $50,000.

The terminology itself bothers Friedberg. “They’re calling it a vaccine, but it’s really immunotherapy,” he noted. “Because a vaccine means you prevent yourself from getting something. Whereas in this case, you’re actually getting rid of something you already have. So I don’t like the word vaccine.”

That distinction matters for how the product is marketed, priced, and ultimately reimbursed. A “vaccine” implies prevention — a public health intervention that society subsidizes. An immunotherapy is a treatment for existing disease — a product that insurers and patients must pay for at market rates.

Regulatory Capture, or How a Process Became a Product

Friedberg’s deeper accusation is regulatory capture. He argues that patenting and gaining FDA approval for a process that was developed with public funding and is already practiced cheaply elsewhere creates an artificial monopoly — one that serves Moderna’s shareholders more than cancer patients.

The economics are stark. If the underlying process — sequence the tumor, make the target protein, inject it — is well-understood, then the marginal cost of treatment should be driven by materials and labor, not by patent rents. Friedberg predicts the neoantigen immunotherapy process will proliferate overseas over the next couple of years, especially at low cost, and will prove very efficacious for certain types of cancer.

That creates a medical tourism arbitrage: American patients with $50,000 but not $500,000 could fly to clinics abroad for treatment. The pressure on Moderna’s pricing model would be immediate and structural.